Video

Eran Orr: Virtual Reality Coming to ADHD

Author(s):

A virtual reality platform could enable ADHD patients to improve cognitive functioning.

The need to leverage new technology may have never been greater in treating attention deficit/hyperactivity disorder (ADHD), especially during the coronavirus disease 2019 (COVID-19) pandemic.

Virtual reality experiences have the opportunity to really help children who are suffering from ADHD, presenting a virtual world that can help deal with some of the symptoms of the disorder.

Recently, XRHealth unveiled a new ADHD virtual reality system aimed at improving well-known ADHD cognitive functioning, including attention, impulsivity, and higher and more complex thinking functions such as initiating, organizing, planning, and fully executing daily tasks.

In the new VR system, each user is monitored for progress based on sustained focus while distractions are present.

The new system is based on the brain’s ability to restructure itself in attempt to overcome existing challenges, referred to as the brain’s plasticity principle.

Clinicians will also have the ability to create, monitor, and adjust the training process at every step within the training system.

The system contains a number of core focuses, including motor activation, a visual and auditory experience that mimics real life activity to improve motor movement, and integrated eye tracking technology.

In an interview with HCPLive®, Evan Orr, Founder and CEO of XRHealth, explained how the new virtual reality platform works and why ADHD lends itself to a virtual reality solution.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.